Table 2.
Characteristics of FSGS patients at the time of kidney transplantation
| Characteristics | All kidney transplants (n = 93) | Recurrence (n = 15) | No recurrence (n = 78) | P-value |
|---|---|---|---|---|
| Age at transplantation (years) | 45.9 ± 14.1 | 36.1 ± 10.3 | 47.8 ± 14 | 0.003 |
| Previous transplantation, n/N (%) | 31/93 (33.3) | 2/15 (13.3) | 29/78 (37.2) | 0.082 |
| Recurrence in previous allograft, n/N (%) | 4/93 (4.3) | 1/15 (6.7) | 3/78 (3.8) | 0.005 |
| BMI at transplantation (kg/m2) | 25.9 ± 5.6 | 23.4 ± 5.4 | 26.3 ± 5.6 | 0.175 |
| Donor age (years) | 43.5 ± 16.2 | 32.8 ± 13.2 | 45.6 ± 16 | 0.005 |
| Donor source, n/N (%) | 0.367 | |||
| Deceased | 71/93 (76.3) | 11/15 (73.3) | 60/78 (76.9) | |
| Living related | 6/93 (6.5) | 0/15 (0) | 6/78 (7.7) | |
| Living non-related | 2/93 (2.2) | 1/15 (6.7) | 1/78 (1.3) | |
| Donation after circulatory death | 14/93 (15.1) | 3/15 (20) | 11/78 (14.1) | |
| Number of HLA mismatches | 3.79 ± 1.22 | 3.77 ± 0.92 | 3.80 ± 1.29 | 0.945 |
| Cold ischaemia time (min) | 946.1 ± 432.2 | 939.6 ± 301.6 | 947.4 ± 454 | 0.952 |
| Induction therapy, n/N (%)a | 69/93 (74.2) | 9/15 (60) | 61/78 (78.2) | 0.251 |
| Thymoglobulin | 28/93 (30.1) | 4/15 (26.7) | 24/78 (30.8) | 0.671 |
| Basiliximab | 35/93 (37.6) | 5/15 (33.3) | 30/78 (38.5) | – |
| Others | 7/93 (7.6) | 0/15 (0) | 7/78 (8.9) | – |
| Delayed graft function, n/N (%) | 32/93 (34.4) | 8/15 (53.3) | 24/78 (30.8) | 0.200 |
| Acute rejection, n/N (%) | 22/93 (23.7) | 7/15 (46.7) | 15/78 (19.2) | 0.069 |
Values are presented as mean ± SD unless stated otherwise. Bold values highlight variables with statistical significance.
a
Thymoglobulin was used in hyperimmunized recipients and in cases of donation after circulatory death, whereas basiliximab was administered to patients with living donors or to elderly recipients (with elderly donors).